Go Pro
OTCMKTS:MKKGY

Merck KGaA (MKKGY) Stock Price, News & Analysis

Merck KGaA logo
$32.49 -0.07 (-0.20%)
As of 12:15 PM Eastern

About Merck KGaA Stock (OTCMKTS:MKKGY)

Advanced

Key Stats

Today's Range
$32.35
$32.60
50-Day Range
$30.48
$33.83
52-Week Range
$23.73
$34.19
Volume
25,324 shs
Average Volume
94,889 shs
Market Capitalization
$20.99 billion
P/E Ratio
16.74
Dividend Yield
1.08%
Price Target
N/A
Consensus Rating
Hold

Company Overview

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co.; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility. The Life Science division supplies reagents, lab consumables, filtration and chromatography solutions, and bioprocessing technologies to research institutions and biopharmaceutical manufacturers — operations that include the MilliporeSigma brand in the United States and Canada following the acquisition of Sigma‑Aldrich. The Electronics business produces high‑performance materials and specialty chemicals used in semiconductor fabrication, display technologies and other advanced industrial applications.

The company operates globally, serving customers across Europe, the Americas, Asia and other regions through manufacturing sites, research centers and commercial affiliates. Since May 2021 Merck KGaA has been led by Chair of the Executive Board and CEO Belén Garijo. Merck emphasizes integrated R&D and partnerships to support pharmaceutical development, laboratory science and materials innovation, positioning itself as a diversified supplier to healthcare, research and high‑technology industries.

AI Generated. May Contain Errors.

Merck KGaA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

MKKGY MarketRank™: 

Merck KGaA scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Merck KGaA has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Merck KGaA has only been the subject of 3 research reports in the past 90 days.

  • Read more about Merck KGaA's stock forecast and price target.
  • Earnings Growth

    Earnings for Merck KGaA are expected to grow by 5.18% in the coming year, from $1.93 to $2.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merck KGaA is 16.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.21.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merck KGaA is 16.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.74.

  • Price to Earnings Growth Ratio

    Merck KGaA has a PEG Ratio of 2.65. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Merck KGaA has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Merck KGaA's valuation and earnings.
  • Percentage of Shares Shorted

    0.00% of the float of Merck KGaA has been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 0.16, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merck KGaA has recently increased by 54.01%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Merck KGaA pays a meaningful dividend of 1.08%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Merck KGaA does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Merck KGaA is 18.04%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Merck KGaA will have a dividend payout ratio of 17.24% next year. This indicates that Merck KGaA will be able to sustain or increase its dividend.

  • Read more about Merck KGaA's dividend.
  • News Sentiment

    Merck KGaA has a news sentiment score of -1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Merck KGaA this week, compared to 2 articles on an average week.
Receive MKKGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MKKGY Stock News Headlines

Merck KGaA (OTCMKTS:MKKGY) Short Interest Down 39.8% in July
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.tc pixel
Merck Lifts Guidance on Life Science, Electronics
Merck KGaA (MKKGY) Stock Forecasts
See More Headlines

MKKGY Stock Analysis - Frequently Asked Questions

Merck KGaA's stock was trading at $28.68 at the beginning of 2026. Since then, MKKGY shares have increased by 13.5% and is now trading at $32.5380.

Merck KGaA (OTCMKTS:MKKGY) released its earnings results on Wednesday, May, 13th. The company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.14. The business had revenue of $6.03 billion for the quarter, compared to analysts' expectations of $5.93 billion. Merck KGaA had a net margin of 11.20% and a trailing twelve-month return on equity of 8.19%.

Shares of MKKGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/13/2026
Today
8/26/2026
Next Earnings (Estimated)
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:MKKGY
Previous Symbol
OTCMKTS:MKKGY
CIK
N/A
Employees
62,461
Year Founded
1668

Profitability

EPS (Trailing Twelve Months)
$1.94
Trailing P/E Ratio
16.74
Forward P/E Ratio
16.83
P/E Growth
2.65
Net Income
$2.95 billion
Net Margins
11.20%
Pretax Margin
15.44%
Return on Equity
8.19%
Return on Assets
4.61%

Debt

Debt-to-Equity Ratio
0.36
Current Ratio
1.51
Quick Ratio
1.00

Sales & Book Value

Annual Sales
$23.87 billion
Price / Sales
0.88
Cash Flow
$8.62 per share
Price / Cash Flow
3.77
Book Value
$50.18 per share
Price / Book
0.65

Miscellaneous

Outstanding Shares
646,210,000
Free Float
N/A
Market Cap
$20.99 billion
Optionable
Not Optionable
Beta
0.98

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:MKKGY) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners